Deep Brain Stimulation in Moroccan Patients With Parkinson's Disease: The Experience of Neurology Department of Rabat

Rahmani, Mounia; Benabdeljlil, M.; Bellakhdar, F.; Faris, M. El Alaoui; Jiddane, M.; Bayad, Khalil El; Boutbib, Fatima; Rachid, R.; Gana, R.; Hassani, M.R. El; Fatemi, Nizar El; Fikri, Meryem; Sanhaji, Siham; Tassine, H.; Balrhiti, Imane El Alaoui; Hadri, Souad El; Kettani, N. Ech-Cherif El; Abbadi, Najia El; Amor, Ben; Moussaoui, Abdelmjid; Semlali, Afifa; Aidi, Saadia; Benhaddou, E.H. Ait; Benomar, Ali; Bouhouche, Ahmed; Yahyaoui, M.; Khamlichi, Abdeslam El; Ouahabi, Abdessamad El; Maaqili, R.; Tibar, Houyam; Arkha, Yasser; Melhaoui, Adyl; Benazzouz, Abdelhamid; Regragui, W.

doi:10.3389/fneur.2018.00532

Cited by 10 publications

(7 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main descriptive characteristics of the eligible studies are summarized in Table 1. All studies were of cohort design yielding a total sample size of 12,258 participants (10,42–106). The follow‐up period ranged from 0.5 to 22 years (median: 3.35 years).…”

Section: Resultsmentioning

confidence: 99%

Deep Brain Stimulation-Related Surgical Site Infections: A Systematic Review and Meta-Analysis

Καντζάνου

Korfias

Panourias

et al. 2021

Neuromodulation: Technology at the Neural Interface

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Deep Brain Stimulation-Related Surgical Site Infections: A Systematic Review and Meta-Analysis

Καντζάνου

Korfias

Panourias

et al. 2021

Neuromodulation: Technology at the Neural Interface

View full text Add to dashboard Cite

“…14,32 In total, 13 patients had either appearance of a mood disorder or recurrence of a previously diagnosed mood disorder. 10,25,30,37,39 In total, 136 patients developed postoperative confusion, delirium, or psychosis. 3,13,16,20,21,24,30,[37][38][39][40][41][42]…”

Section: Neurological Complicationsmentioning

confidence: 99%

“…10,25,30,37,39 In total, 136 patients developed postoperative confusion, delirium, or psychosis. 3,13,16,20,21,24,30,[37][38][39][40][41][42]…”

Section: Neurological Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Estimating the Risk of Deep Brain Stimulation in the Modern Era: 2008 to 2020

Koh¹,

Golubovsky²,

Rammo³

et al. 2021

Operative Surg.

View full text Add to dashboard Cite

BACKGROUND Deep brain stimulation (DBS) was first approved by the United States Food and Drug Administration in 1997. Although the fundamentals of DBS remain the same, hardware, software, and imaging have evolved significantly. OBJECTIVE To test our hypothesis that the aggregate complication rate in the medical literature in the past 12 years would be lower than what is often cited based on early experience with DBS surgery. METHODS PubMed, PsycINFO, and EMBASE were queried for studies from 2008 to 2020 that included patients treated with DBS from 2007 to 2019. This yielded 34 articles that evaluated all complications of DBS surgery, totaling 2249 patients. RESULTS The overall complication rate in this study was 16.7% per patient. There was found to be a systemic complication rate of 0.89%, intracranial complication rate of 2.7%, neurological complication rate of 4.6%, hardware complication rate of 2.2%, and surgical site complication rate of 3.4%. The infection and erosion rate was 3.0%. CONCLUSION This review suggests that surgical complication rates have decreased since the first decade after DBS was first FDA approved. Understanding how to minimize complications from the inception of a technique should receive more attention.

show abstract

“…Apart from a few centers in South Africa [130] and North Africa (Egypt [131] and Morocco [132]), expertise and facilities for DBS are in short supply across Africa. This, therefore, limits treatment options for many patients with advanced disease who no longer get benefits from dopaminergic medications and would otherwise benefit from this procedure.…”

Section: Challenges Of Parkinson's Disease Management In Low Resource Settingsmentioning

confidence: 99%

Parkinson’s disease – a review of pathogenesis, recent advances in management, and challenges of care in sub-Saharan Africa

Makanjuola¹,

Taiwo²,

Yaria³

et al. 2021

J Global Med

View full text Add to dashboard Cite

Parkinson’s disease (PD) remains a common neurodegenerative movement disorder with significant morbidity, which is expected to increase worldwide in the coming decades. Since its initial description, much has been elucidated about its etiology, pathogenesis, and the role of genetic and environmental risk factors. Effective treatments, including surgical therapies, have been discovered. Despite these strides, many questions remain unanswered; PD remains an active research area with ongoing efforts to discover newer treatment modalities and identify neuroprotective strategies. As with many neurological conditions, there is an unequal distribution of health resources, resulting in some management challenges in low resource settings, especially sub-Saharan Africa (SSA). In this communication, we provide an overview of PD etiopathogenesis, including genetics and management strategies, including some recent advances with respect to treatment options and disease modification approaches. Finally, we discuss some challenges of PD management in low-resource settings and highlight efforts to turn the tide.

show abstract

Deep Brain Stimulation in Moroccan Patients With Parkinson's Disease: The Experience of Neurology Department of Rabat

Cited by 10 publications

References 97 publications

Deep Brain Stimulation-Related Surgical Site Infections: A Systematic Review and Meta-Analysis

Deep Brain Stimulation-Related Surgical Site Infections: A Systematic Review and Meta-Analysis

Estimating the Risk of Deep Brain Stimulation in the Modern Era: 2008 to 2020

Parkinson’s disease – a review of pathogenesis, recent advances in management, and challenges of care in sub-Saharan Africa

Contact Info

Product

Resources

About